Is filgotinib already on the market in the country? What is the situation?

Filgotinib(Filgotinib) is a highly selective Janus kinase (JAK) inhibitor. It was first used in overseas research for the treatment of autoimmune diseases, and has received widespread attention especially in the fields of rheumatoid arthritis and inflammatory bowel disease. For domestic patients, one of the most concerning issues is whether filgotinib has been launched in China and whether it can be obtained through formal channels.

Up to now, the original drug of filgotinib has not been officially approved for marketing in China, and therefore it has not been included in the national medical insurance catalog. This means that the drug is temporarily unavailable through regular prescriptions in domestic hospitals or pharmacies, and its specific pricing system has not yet been announced. Compared with some JAK inhibitors that have been introduced into the country, filgotinib is still "unmarketed" in China, and the relevant approval and introduction progress still need to be subject to official information.

In overseas markets, filgotinib has been approved and put into use in some countries and regions. It is commonly used as the European version of the original drug, with specifications of 200mg × 30 tablets. It is mainly used for long-term oral treatment. From the perspective of international pricing, its price level is usually in a similar range to similar JAK inhibitors. However, due to the large differences in drug pricing, medical insurance coverage and supply systems in different countries, when domestic patients learn about the price through overseas channels, it can often only be used as a reference and cannot be directly equivalent to the future domestic selling price.

Generally speaking, filgotinib is still a "not yet marketed drug" in China, and there are obvious limitations in terms of medical insurance coverage and market accessibility. For patients with potential treatment needs, it is recommended to continue to pay attention to domestic regulatory developments and carefully evaluate the feasibility and safety of treatment options under the guidance of professional doctors.

Reference materials:https://www.medicines.org.uk/emc/product/11809/smpc